Parabilis Medicines (PBLS) Stock Analysis
NASDAQHealthcareBiotechnology
What Parabilis Medicines does
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Key metrics
ETFs linked to PBLS
Broad-market and Healthcare sector ETFs an investor holding Parabilis Medicines is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how PBLS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze PBLS in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Parabilis Medicines?
- Parabilis Medicines trades under the ticker PBLS on NASDAQ.
- Which exchange is PBLS listed on?
- PBLS is listed on NASDAQ.
- What sector does Parabilis Medicines operate in?
- Parabilis Medicines is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze PBLS in a portfolio?
- PortView shows PBLS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.